Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 0.56 |
| ▸ | DRD3 | P35462 | 16/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 6/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468808 | 0.93 | DRD2 (0.58) | DRD2DRD3HTR2AADRA1ADRD4 | |
| SCHEMBL12468792 | 0.82 | HPGD (0.47) | DRD2HTR2AADRA1AHTR1AHTR7 | |
| SCHEMBL12469195 | 0.80 | KCNH2 (0.54) | DRD3ADRA1AHTR1AHTR7OPRM1 | |
| SCHEMBL12468880 | 0.78 | DRD2 (0.46) | DRD2DRD3HTR2AADRA1ADRD4 | |
| SCHEMBL15348353 | 0.76 | HTR7 (0.48) | DRD2HTR2AHTR1AHTR7 | |
| SCHEMBL12469487 | 0.74 | SLC6A2 (0.52) | DRD2DRD3HTR2ADRD4OPRM1 | |
| SCHEMBL12469081 | 0.73 | KCNH2 (0.58) | DRD2DRD3HTR2AADRA1ADRD4 | |
| SCHEMBL2782258 | 0.73 | DRD2 (1.00) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL12468893 | 0.73 | SIGMAR1 (0.53) | DRD2DRD3ADRA1AHTR1AHTR7 | |
| SCHEMBL14494878 | 0.72 | DRD2 (0.76) | DRD2DRD3HTR2AADRA1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | EPIOMED THERAPEUTICS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2012051601-A2 | HETEROARYLTHIO COMPOUNDS | EPIOMED THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | NLN, HTT, ABAT | DRD2 2163/4885DRD3 2127/4885HTR2A 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.